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Discussion: MPNST are a rare sarcoma but more common in patients with NF1 
who have malignant transformation of plexiform neuromas. Thoracic metastases 
are rare and few cases of anesthetic management  exist.  Patients  with  NF1  
have neurofibromas and neuromas throughout the body, which can obstruct the 
airway and complicate regional anesthesia. NF1 patients may also present with 
restrictive lung disease secondary to pulmonary fibrosis and kyphosis. Given these 
considerations, we used a video laryngoscope and avoided muscle relaxants as   
a precaution to avoid airway compromise. The use of regional anesthesia was 
essential to minimize postoperative pain and permit successful extubation. 
References: 
1. Hirsch NP et al. Neurofibromatosis: clinical presentations and anaesthetic 
implications. BJA. 2001;86(4):555-564. 
2. Boland JM et al. Intrathoracic peripheral nerve sheath tumors-a 
clinicopathological study of 75 cases. Hum Pathol. 2015;46(3):419-425. 
Learning points: Anesthetic management for NF1 should include: careful airway 
management, the judicious use of muscle relaxants, and the use of regional 
anesthesia for the resection of a thoracic sarcoma. 
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Background: During tanscatheter aortic valve implantation (TAVI), normalization 
of left ventricular afterload induced by prosthetic valve deployment is expected to 
result in rapid improvement of systolic function and consequent improvement in 
diastolic function. Previously, we reported a rapid increase in the left ventricular end- 
diastolic pressure (LVEDP) after deployment with a balloon expandable prosthetic 
valve [1]. In this study, we aimed to determine the effect of types of prosthetic valves 
for TAVI on the LVEDP. 
Methods: This retrospective observational study included patients who had 
undergoing transfemoral TAVI since May 2016. The patients were classified into two 
groups by valve type: patients treated with a balloon-expandable valve (group B) 
and those treated with self-expandable valve (group S). The results of intraoperative 
LVEDP measurements an intracardiac catheter before and after prosthetic valve 
deployment were compared between the two groups. In order to eliminate the effect 
of artic regurgitation on the LVEDP, subanalysis was performed on patients with 
mild or less aortic regurgitation assessed by echocardiography performed before 
and/or after valve deployment. Statistical analysis was performed using a nonpaired 
t test, the Mann Whitney U test and two way analysis of variance. A p value of < 0.05 
was considered as significant. 
Result: The study sample consisted of 99 patients (group B, 70; group S, 29). The 
LVEDP significantly increased after deployment in group B (11.4±4.2 to 13.2±5.7 
mmHg), but significantly decreased in group S (14.0±6.2 to 13.4±5.4 mmHg). After 
excluding 36 patients with moderate or greater aortic regurgitation, 63 patients 
were subanalyzed, in whom the LVEDP also significantly increased after valve 
deployment in group B (11.2±4.2 to 13.2±5.5 mmHg), but significantly decreased 
after valve deployment in group S (14.7±5.2 to 12.1±4.1 mmHg). 
Conclusion: TAVI with balloon-expandable prosthetic valve may increase the 
LVEDP compared with that with a self-expandable prosthetic valve. 
References: 
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Background and Goal of Study: To maintain systemic perfusion pressure 
intraoperatively, phenylephrine (PE) and ephedrine (E) are usually the drugs of 
choice. Yet, the effect of these agents on cerebral blood flow and brain oxygenation 
is still controversial. Meng et al.[1] reported a negative effect of PE on cerebral 
tissue oxygen saturation  (SctO2) whereas  SctO2 remained  unaffected  with  E. 
In contrast, Pennenkamp et al. [2]observed a significant positive effect of E on 
SctO2. However, to minimize bias, surgical stimulation should be homogeneous 
and administration of drugs must be standardized. Therefore, our study assessed 
the effect of PE and E on SctO2 in patients undergoing percutaneous transluminal 
angioplasty. A standardized protocol to maintain normotension was used. 
Materials and Methods: A randomized four-treatment cross-over trial was applied 
in 28 patients under BIS-titrated anaesthesia with sevoflurane. Patients were 
randomized into four different groups (Figure 1). If MAP decreased more than  
20% from baseline, incremental doses of PE or E were given in order to return     
to baseline.SctO2 was measured with near-infrared spectroscopy. SctO2and other 
physiologic variables were recorded. Linear mixed-modelling was used to assess 
the effects of PE and E on SctO2. 
 
 
Results and Discussion: No crossover effect was observed between agents. 
Following PE, SctO2decreased significantly (-2.1% [-3.2%; -1.1%], p<0.001), 
whereas no changes were seen with E (0.0% [-1.0%; 1.0%]. The cause and the 
clinical relevance of the small decrease in SctO2after PE administration is still 
unknown, but our results indicate that in terms of cerebral oxygenation, E might  
be preferred. 
Conclusion: After bolus administration, PE caused a significant decrease in SctO2, 
whereas E exerted no changes in SctO2. 
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Background and Goal of Study: One of the most innovative medical progress in 
the treatment of end stage heart failure is the development of continuous flow left 
ventricular assist devices (cfLVAD). However, the surgical implantation of a cfLVAD 
is a high-risk procedure and might be complicated by postoperative vasoplegic 
syndrome (VS), right ventricular failure, renal failure with possible need for renal 
replacement therapy and mortality. In the current study, we examined whether the 
occurrence of postoperative VS affects short-term (<6 months) postoperative renal 
function in patients undergoing cfLVAD implantation. 
Materials and Methods: Included were patients scheduled for primary cfLVAD 
implantation. Patients were classified as vasoplegic if they had the following 
conditions for at least three consecutive hours during the first 48 hours after ICU 
arrival: low systemic vascular resistance (SVR <800 dynes/s/cm¯⁵) and/or low 
mean arterial pressure (MAP <50 mmHg), preserved cardiac index (CI >2.5 liter/ 
minute/m²) and high vasopressor requirements (noradrenaline >200 ng/kg/min or 
equivalent doses of other vasopressors. Renal function, expressed as glomerular 
filtration rate (GFR), was measured prior to and at 1, 2, 3 and 6 months after cfLVAD 
implantation. A generalized mixed model was used to compare baseline GFR 
measurements between patients with and without VS, as well as their GFR courses 
over this six month follow up period. Relative risks (RR) were calculated for the 
association between VS and renal failure, the need of renal replacement therapy 
and 30-day and one-year all-cause mortality. 
Results and discussion: In this retrospective study, 160 patients were included, of 
which 42 patients (26%) developed postoperative VS. They had a significantly lower 
GFR before cfLVAD implantation (p=0.007), a different course in renal function after 
cfLVAD implantation (p<0.0001), a higher relative risk to develop renal failure (RR 
3.4, 95% confidence interval (CI) 1.9-6.1), required more often renal replacement 
therapy (RR: 4.8,CI 2.0-11.4) and died more often (RR: 26.7, CI 10.1-703) 
compared to patients without postoperative VS. 
Conclusion: Our cohort study revealed vasoplegic syndrome being associated with 
a worse pre-operative renal function, which continues over a six-month period post- 
cfLVAD implantation compared to non-vasoplegia patients. 
